Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

被引：0
|
作者：
Pilotto, Sara [1 ]
Bria, Emilio [1 ]
机构：
[1] Univ Verona, Azienda Osped Univ Integrata, GB Rossi Acad Hosp, Med Oncol, Verona, Italy
来源：
LUNG CANCER MANAGEMENT | 2013年 / 2卷 / 02期
关键词：
D O I：
10.2217/LMT.12.57
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：89 / 92
页数：4
相关论文
共 50 条
  • [21] First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
    Holleman, Marscha S.
    van Tinteren, Harm
    Groen, Harry J. M.
    Al, Maiwenn J.
    Uyl-de Groot, Carin A.
    ONCOTARGETS AND THERAPY, 2019, 12 : 1413 - 1421
  • [22] EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
    Kao, Hsiang-Fong
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    FUTURE ONCOLOGY, 2013, 9 (07) : 991 - 1003
  • [23] Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
    Sullivan, Ivana
    Planchard, David
    FRONTIERS IN MEDICINE, 2017, 3
  • [24] Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors A Review
    Piotrowska, Zofia
    Sequist, Lecia V.
    JAMA ONCOLOGY, 2016, 2 (07) : 948 - 954
  • [25] Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer
    Lu, Xiaotong
    Wang, Jingbo
    Wang, Chunyu
    Liang, Jun
    Zhou, Zongmei
    Chen, Dongfu
    Feng, Qinfu
    Xiao, Zefen
    Hui, Zhouguang
    Lu, Jima
    Zhang, Tao
    Liu, Wenyang
    Wang, Jianyang
    Wang, Xin
    Deng, Lei
    Zhai, Yirui
    Bi, Nan
    Wang, Luhua
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [26] Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer
    Lu, Xiaotong
    Wang, Jingbo
    Wang, Chunyu
    Liang, Jun
    Zhou, Zongmei
    Chen, Dongfu
    Feng, Qinfu
    Xiao, Zefen
    Hui, Zhouguang
    Lu, Jima
    Zhang, Tao
    Liu, Wenyang
    Wang, Jianyang
    Wang, Xin
    Deng, Lei
    Zhai, Yirui
    Bi, Nan
    Wang, Luhua
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [27] Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
    Adderley, Helen
    Ackermann, Christoph Jakob
    Califano, Raffaele
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [28] Treatment choice in EGFR-mutant non-small-cell lung cancer
    Brueckl, Wolfgang M.
    LANCET ONCOLOGY, 2017, 18 (11): : 1425 - 1426
  • [29] Spontaneously expectorated EGFR-mutant non-small-cell lung cancer
    Sumi, Toshiyuki
    Terai, Kotomi
    Chiba, Hirofumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (11) : 1094 - 1095
  • [30] Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
    Moriya, Tetsuji
    Hamaji, Masatsugu
    Yoshizawa, Akihiko
    Miyata, Ryo
    Noguchi, Misa
    Tamari, Shigeyuki
    Chiba, Naohisa
    Miyamoto, Hideaki
    Toyazaki, Toshiya
    Tanaka, Satona
    Yamada, Yoshito
    Yutaka, Yojiro
    Nakajima, Daisuke
    Ohsumi, Akihiro
    Menju, Toshi
    Date, Hiroshi
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 34 (03) : 416 - 423
12345